Adicet Bio

CEO Chen Schor has steered the pivot from oncology to autoimmune, executed financings, and narrowed focus to the most promising assets. The addition of CMO Julie Maltzman, M.D. (Jan 2025) strengthens clinical leadership across autoimmune and oncology. Governance appears standard for a small‑cap biotech.

We do not see founder‑owner alignment or a decade‑long compounding record typical of our highest‑quality holdings, but the current team has relevant experience to run the planned studies.